GlobalData’s new report, “Drug Delivery Devices Market Outlook in Italy to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections” provides key market data on the Italy Drug Delivery Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within four market categories – Central Venous Catheters, Infusion Systems, Metered Dose Inhaler Devices and Needle Free Injections. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
- Market size and company share data for Drug Delivery Devices market categories – Central Venous Catheters, Infusion Systems, Metered Dose Inhaler Devices and Needle Free Injections.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within four market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the four market categories.
- Global corporate-level profiles of key companies operating within the Italy Drug Delivery Devices market.
- Key players covered include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca PLC, Sunovion, Baxter International Inc., Fresenius Kabi AG and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Italy Drug Delivery Devices competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.
Report Highlights GlaxoSmithKline plc
Boehringer Ingelheim GmbH
Fresenius Kabi AG
Baxter International Inc.
B. Braun Melsungen AG
3M Health Care
Consort Medical plc
Becton, Dickinson and Company
Edwards Lifesciences Corporation
JMS CO., LTD.
INJEX - Equidyne Systems
Antares Pharma, Inc.
Bioject Medical Technologies Inc.
Cook Medical Incorporated
GlobalData's clinical trial report, “Psoriasis Global Clinical Trials Review, H1, 2012" provides data on the Psoriasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Psoriasis. It includes an overview of the tri ... more
Promethean Corp. (Promethean) is a New York based Health Care company. The company develops, manufactures and distributes its own products and is also involved in providing various health care services. The company through its wholly owned subsidiary, Ceres Living, produces and sells the AI ... more
GlobalData’s new report, “Austria Neurology Devices Market Outlook to 2018 - Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others” provides key market data on the Austria Neurology Devices market. The report provides value (USD mill ... more
As drug makers continue to jostle for market share and deal with declining revenues from their off-patent blockbuster drugs, M&A activity is showing no indication of slowing down in 2013. Pfizer is not leaving any stone unturned as the company continues its growth. Less than two months afte ... more
US demand for influenza vaccines will remain high in the coming decade, following a post-flu pandemic spike, predicts business intelligence provider GlobalData.
According to the company’s latest epidemiology report, seasonal influenza vaccine demand will increase from the 142 million expect ... more
Biotech companies are exploring alternative options to supplement their in-house research and development (R&D), abandoning the traditional blockbuster drug model to instead pursue deals and buy their way to success, says healthcare intelligence providers GlobalData in a new report, which e ... more